Careers  |  Sign In  |  Register

Dr. Daver on the Advancing Treatment Landscape in AML

Naval G. Daver, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlights findings from the randomized phase 3 VIALE trial. The VIALE trial demonstrated significant overall survival and complete response with the combination of azacitidine plus venetoclax. Dr. Daver explains azacitidine has historically been a monotherapy but may have even greater potential as a combination therapy.

Click here to learn more.